By Justin Petrone

CombiMatrix's decision to focus all of its resources on its diagnostics business and abandon its play in the research arena appears to be paying off.

The company reported last week that its third-quarter revenues increased 68 percent on diagnostic testing sales, while its net loss for the quarter shrank by half.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.